Serial Measurements of Off-Thyroxine Serum TSH and Thyroglobulin Levels to Predict Local and/or Systemic Metastasis of Papillary Thyroid Cancer after Total Thyroidectomy
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives: Off-thyroxine serum thyroglobulin (Tg) level is important to predict metastatic disease (MD) in papillary thyroid cancer (PTC); however, it is unclear whether a single off-thyroxine Tg level is sufficient for predicting MD. In this study, we determined whether serial measurement of off-thyroxine serum Tg level can predict metastasis in PTC patients after total thyroidectomy. Materials and Methods: We enrolled 140 PTC patients in whom serum thyroid-stimulating hormone (TSH) and Tg levels were measured 7 days before radio-iodine (RAI) treatment (TSHA and TgA) and on the day of RAI treatment (TSHB and TgB) with withholding L-thyroxine for 4 weeks before RAI treatment. The values of TSHinc (TSHB-TSHA) and Tginc (TgB-TgA), Tgratio (TgB/TgA),Tginc/TSHinc and Tgratio/TSHinc were calculated. Tginc/TSHinc and Tgratio/TSHinc were tested if those parameters can predict MD in patients with TSHA＞30 μIU/mL and TgA＜10 ng/mL. Results: Forty-four patients had MD and 96had no evidence of MD (non-MD). MD group showed higher levels of TgA, TgB, Tginc, Tginc/TSHinc and Tgratio/TSHinc compared with non-MD group. A significant correlation was found between TSHinc and Tgratio (r=0.669) in MD group. In 43 patients with TSHA＞30 μIU/mL and TgA＜10 ng/mL (MD, 9; non-MD, 34), both Tginc/TSHinc (100%)and Tgratio/TSHinc (89%) had higher sensitivities for predicting MD than TgB (78%). Conclusion: With the increment in serum Tg corrected for the increment in serum TSH, serial measurements of off-thyroxine serum TSH and Tg levels can help predict PTC metastasis.
Abstract
Background and Objectives: Off-thyroxine serum thyroglobulin (Tg) level is important to predict metastatic disease (MD) in papillary thyroid cancer (PTC); however, it is unclear whether a single off-thyroxine Tg level is sufficient for predicting MD. In this study, we determined whether serial measurement of off-thyroxine serum Tg level can predict metastasis in PTC patients after total thyroidectomy. Materials and Methods: We enrolled 140 PTC patients in whom serum thyroid-stimulating hormone (TSH) and Tg levels were measured 7 days before radio-iodine (RAI) treatment (TSHA and TgA) and on the day of RAI treatment (TSHB and TgB) with withholding L-thyroxine for 4 weeks before RAI treatment. The values of TSHinc (TSHB-TSHA) and Tginc (TgB-TgA), Tgratio (TgB/TgA),Tginc/TSHinc and Tgratio/TSHinc were calculated. Tginc/TSHinc and Tgratio/TSHinc were tested if those parameters can predict MD in patients with TSHA＞30 μIU/mL and TgA＜10 ng/mL. Results: Forty-four patients had MD and 96had no evidence of MD (non-MD). MD group showed higher levels of TgA, TgB, Tginc, Tginc/TSHinc and Tgratio/TSHinc compared with non-MD group. A significant correlation was found between TSHinc and Tgratio (r=0.669) in MD group. In 43 patients with TSHA＞30 μIU/mL and TgA＜10 ng/mL (MD, 9; non-MD, 34), both Tginc/TSHinc (100%)and Tgratio/TSHinc (89%) had higher sensitivities for predicting MD than TgB (78%). Conclusion: With the increment in serum Tg corrected for the increment in serum TSH, serial measurements of off-thyroxine serum TSH and Tg levels can help predict PTC metastasis.
참고문헌 (20)
- Iervasi A, "Serum thyroglobulin measurement: clinical background and main methodological aspects with clinical impact", Biomed Pharmacother, 60(8), pp.414~424 (2006)
- Francis Z, "Serum thyroglobulin determination in thyroid cancer patients", Best Pract Res Clin Endocrinol Metab, 22(6), pp.1039~1046 (2008)
- Van Herle AJ, "Radioimmunoassay for measurement of thyroglobulin in human serum", J Clin Invest, 52(6), pp.1320~1327 (1973)
- Torrens JI, "Serum thyroglobulin measurement. Utility in clinical practice", Endocrinol Metab Clin North Am, 30(2), pp.429~467 (2001)
- Eustatia-Rutten CF, "Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis", Clin Endocrinol (Oxf), 61(1), pp.61~74 (2004)
- Mazzaferri EL, "A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma", J Clin Endocrinol Metab, 88(4), pp.1433~1441 (2003)
- Cooper DS, "Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer", Thyroid, 19(11), pp.1167~1214 (2009)
- Mazzaferri EL, "Empirically treating high serum thyroglobulin levels", J Nucl Med, 46(7), pp.1079~1088 (2005)
- Silberstein EB, "The problem of the patient with thyroglobulin elevation but negative iodine scintigraphy: the TENIS syndrome", Semin Nucl Med, 41(2), pp.113~120 (2011)
- Lin Y, "Predictive value of preablation stimulated thyroglobulin and thyroglobulin", thyroid-stimulating hormone ratio in differentiated thyroid cancer, 2011, pp.36(12), 1102~1105
- Robbins RJ, "Factors influencing the basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma", J Clin Endocrinol Metab, 89(12), pp.6010~6016 (2004)
- Spencer CA, "Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement", Thyroid, 9(5), pp.435~441 (1999)
- Bachelot A, "Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma", Thyroid, 12(8), pp.707~711 (2002)
- Pellegriti G, "The diagnostic use of the rhTSH", thyroglobulin test in differentiated thyroid cancer patients with persistent disease and low thyroglobulin levels, 2003, pp.58(5), 556~561
- Ma C, "Is empiric 131I therapy justified for patients with positive thyroglobulin and negative 131I wholebody scanning results?", J Nucl Med, 46(7), pp.1164~1170 (2005)
- Kim WG, "Empiric high-dose 131-iodine therapy lacks efficacy for treated papillary thyroid cancer patients with detectable serum thyroglobulin, but negative cervical sonography and 18F-fluorodeoxyglucose positron emission tomography scan", J Clin Endocrinol Metab, 95(3), pp.1169~1173 (2010)
- Pacini F, "Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients", J Clin Endocrinol Metab, 86(9), pp.4092~4097 (2001)
- Robbins RJ, "Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma?", J Clin Endocrinol Metab, 87(7), pp.3242~3247 (2002)
- 박은경, "Recurrent", metastatic thyroid carcinomas false negative for serum thyroglobulin but positive by posttherapy I-131 whole body scans, 200902, pp.36(2), 172~179
- Ministry of Health and Welfare, "The Korea central cancer registry. Annual report of cancer statistics in Korea in 2008", Ministry of Health and Welfare, ~ (2010)